vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and PRA GROUP INC (PRAA). Click either name above to swap in a different company.
PRA GROUP INC is the larger business by last-quarter revenue ($333.4M vs $247.1M, roughly 1.3× ANI PHARMACEUTICALS INC). PRA GROUP INC runs the higher net margin — 17.0% vs 11.1%, a 5.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 13.7%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-90.4M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 14.2%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
PRA Group, Inc. is a publicly traded debt buyer and debt collection company based in Norfolk, Virginia. The company buys delinquent consumer debt from credit card issuers and other financial institutions at a discount and pursues collection of the full debt owed. Founded in 1996, PRA Group employs more than 3200 people in 18 countries.
ANIP vs PRAA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $333.4M |
| Net Profit | $27.5M | $56.5M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 37.7% |
| Net Margin | 11.1% | 17.0% |
| Revenue YoY | 29.6% | 13.7% |
| Net Profit YoY | 367.5% | 206.3% |
| EPS (diluted) | $1.14 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $333.4M | ||
| Q3 25 | $227.8M | $311.1M | ||
| Q2 25 | $211.4M | $287.7M | ||
| Q1 25 | $197.1M | $269.6M | ||
| Q4 24 | $190.6M | $293.2M | ||
| Q3 24 | $148.3M | $281.5M | ||
| Q2 24 | $138.0M | $284.2M | ||
| Q1 24 | $137.4M | $255.6M |
| Q4 25 | $27.5M | $56.5M | ||
| Q3 25 | $26.6M | $-407.7M | ||
| Q2 25 | $8.5M | $42.4M | ||
| Q1 25 | $15.7M | $3.7M | ||
| Q4 24 | $-10.3M | $18.5M | ||
| Q3 24 | $-24.2M | $27.2M | ||
| Q2 24 | $-2.3M | $21.5M | ||
| Q1 24 | $18.2M | $3.5M |
| Q4 25 | 14.1% | 37.7% | ||
| Q3 25 | 15.9% | -101.4% | ||
| Q2 25 | 6.6% | 29.6% | ||
| Q1 25 | 13.3% | 27.7% | ||
| Q4 24 | -2.3% | 32.1% | ||
| Q3 24 | -13.8% | 32.0% | ||
| Q2 24 | 3.7% | 31.4% | ||
| Q1 24 | 14.8% | 26.0% |
| Q4 25 | 11.1% | 17.0% | ||
| Q3 25 | 11.7% | -131.0% | ||
| Q2 25 | 4.0% | 14.7% | ||
| Q1 25 | 8.0% | 1.4% | ||
| Q4 24 | -5.4% | 6.3% | ||
| Q3 24 | -16.3% | 9.6% | ||
| Q2 24 | -1.7% | 7.6% | ||
| Q1 24 | 13.2% | 1.4% |
| Q4 25 | $1.14 | $1.47 | ||
| Q3 25 | $1.13 | $-10.43 | ||
| Q2 25 | $0.36 | $1.08 | ||
| Q1 25 | $0.69 | $0.09 | ||
| Q4 24 | $-0.45 | $0.47 | ||
| Q3 24 | $-1.27 | $0.69 | ||
| Q2 24 | $-0.14 | $0.54 | ||
| Q1 24 | $0.82 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $104.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $979.9M |
| Total Assets | $1.4B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $104.4M | ||
| Q3 25 | $262.6M | $107.5M | ||
| Q2 25 | $217.8M | $131.6M | ||
| Q1 25 | $149.8M | $128.7M | ||
| Q4 24 | $144.9M | $105.9M | ||
| Q3 24 | $145.0M | $141.1M | ||
| Q2 24 | $240.1M | $118.9M | ||
| Q1 24 | $228.6M | $108.1M |
| Q4 25 | $540.7M | $979.9M | ||
| Q3 25 | $505.8M | $928.5M | ||
| Q2 25 | $436.8M | $1.3B | ||
| Q1 25 | $418.6M | $1.2B | ||
| Q4 24 | $403.7M | $1.1B | ||
| Q3 24 | $405.9M | $1.2B | ||
| Q2 24 | $455.8M | $1.1B | ||
| Q1 24 | $452.0M | $1.1B |
| Q4 25 | $1.4B | $5.1B | ||
| Q3 25 | $1.4B | $5.0B | ||
| Q2 25 | $1.3B | $5.4B | ||
| Q1 25 | $1.3B | $5.1B | ||
| Q4 24 | $1.3B | $4.9B | ||
| Q3 24 | $1.3B | $4.9B | ||
| Q2 24 | $920.8M | $4.7B | ||
| Q1 24 | $914.5M | $4.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-85.5M |
| Free Cash FlowOCF − Capex | $29.1M | $-90.4M |
| FCF MarginFCF / Revenue | 11.8% | -27.1% |
| Capex IntensityCapex / Revenue | 0.5% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.10× | -1.51× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-169.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-85.5M | ||
| Q3 25 | $44.1M | $-10.1M | ||
| Q2 25 | $75.8M | $-12.9M | ||
| Q1 25 | $35.0M | $-52.6M | ||
| Q4 24 | $15.9M | $-94.6M | ||
| Q3 24 | $12.5M | $-35.0M | ||
| Q2 24 | $17.4M | $-29.5M | ||
| Q1 24 | $18.3M | $-73.0M |
| Q4 25 | $29.1M | $-90.4M | ||
| Q3 25 | $38.0M | $-11.3M | ||
| Q2 25 | $71.8M | $-14.2M | ||
| Q1 25 | $32.5M | $-53.5M | ||
| Q4 24 | $13.5M | $-98.6M | ||
| Q3 24 | $7.7M | $-36.1M | ||
| Q2 24 | $13.0M | $-30.8M | ||
| Q1 24 | $13.7M | $-73.5M |
| Q4 25 | 11.8% | -27.1% | ||
| Q3 25 | 16.7% | -3.6% | ||
| Q2 25 | 34.0% | -4.9% | ||
| Q1 25 | 16.5% | -19.8% | ||
| Q4 24 | 7.1% | -33.6% | ||
| Q3 24 | 5.2% | -12.8% | ||
| Q2 24 | 9.4% | -10.8% | ||
| Q1 24 | 10.0% | -28.8% |
| Q4 25 | 0.5% | 1.4% | ||
| Q3 25 | 2.7% | 0.4% | ||
| Q2 25 | 1.9% | 0.4% | ||
| Q1 25 | 1.3% | 0.3% | ||
| Q4 24 | 1.3% | 1.4% | ||
| Q3 24 | 3.2% | 0.4% | ||
| Q2 24 | 3.2% | 0.5% | ||
| Q1 24 | 3.3% | 0.2% |
| Q4 25 | 1.10× | -1.51× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | -0.30× | ||
| Q1 25 | 2.23× | -14.37× | ||
| Q4 24 | — | -5.13× | ||
| Q3 24 | — | -1.29× | ||
| Q2 24 | — | -1.37× | ||
| Q1 24 | 1.00× | -21.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PRAA
| GB | $170.1M | 51% |
| Other | $163.3M | 49% |
